menu
    • menu
    [{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tomivosertib","moa":"Mapk 1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Locust Walk","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"Tomivosertib","moa":"MNK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.23999999999999999,"dosageForm":"Oral","sponsorNew":"Effector Therapeutics \/ Locust Walk","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Locust Walk"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tomivosertib","moa":"MNK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tomivosertib","moa":"MNK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Northwestern University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Tomivosertib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Effector Therapeutics \/ Northwestern University","highestDevelopmentStatusID":"6","companyTruncated":"Effector Therapeutics \/ Northwestern University"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Tomivosertib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Effector Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Tomivosertib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Effector Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tomivosertib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tomivosertib

    Menu

    Tomivosertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tomivosertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            eFFECTOR Announces Topline Results of Phase 2 Trial of Tomivosertib in Lung Cancer

                            Details : eFT508 (tomivosertib) is a potent and highly selective MNK inhibitor, small molecule drug candidate, which is being evaluated in combination with pembrolizumab for non-small cell lung cancer.

                            Brand Name : eFT508

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 04, 2024

                            Lead Product(s) : Tomivosertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tomivosertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            eFFECTOR Closes $15 Million Registered Direct Offering Priced At-The-Market

                            Details : The net proceeds will focus on the development of eFT508 (tomivosertib), which is a small molecule inhibitor of MNK used for the treatment of patients with metastatic non-small cell lung cancer.

                            Brand Name : eFT508

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 29, 2024

                            Lead Product(s) : Tomivosertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tomivosertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Vidac Secures Approval for Next Phase of Clinical Study in Cutaneous T-Cell Lymphoma

                            Details : The net proceeds will be used to advance company's pipeline including, eFT508 (tomivosertib), an oral small molecule inhibitor of MNK1 and MNK2 and currently in Phase II for Head And Neck Cancer.

                            Brand Name : eFT508

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : Tomivosertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tomivosertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Northwestern University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on a...

                            Details : The collaboration aims to evaluate eFT508 (tomivosertib), an inhibitor of mitogen-activator protein kinase interacting kinase (MNK) 1 and 2 and blocks phosphorylation of eukaryotic initiation factor 4E, in patients with relapsed/refractory Acute Myeloid ...

                            Brand Name : eFT508

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 24, 2023

                            Lead Product(s) : Tomivosertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Northwestern University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tomivosertib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            eFFECTOR Therapeutics Announces Transition in Clinical Leadership

                            Details : eFT505 (tomivosertib), a potent and highly selective inhibitor of the immunosuppressive kinases MNK-1 and 2, blocks the expression of checkpoint proteins PD-1, PD-L1, and LAG-3 as well as immunosuppressive cytokines IL-6 and IL-8.

                            Brand Name : eFT505

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 04, 2022

                            Lead Product(s) : Tomivosertib,Pembrolizumab,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tomivosertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial

                            Details : Cohort two will assess the safety and efficacy of tomivosertib in combination with pembrolizumab at treatment initiation in the frontline setting. Both cohorts in the trial will have a control arm with placebo in combination with pembrolizumab.

                            Brand Name : eFT508

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 09, 2021

                            Lead Product(s) : Tomivosertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tomivosertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Locust Walk

                            Deal Size : $235.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement

                            Details : Transaction includes up to $175 m in trust at LWAC and a concurrent, fully committed $60 m PIPE offering. The funds will be used to Push eFFECTOR’s pipeline through multiple clinical milestones including expansion of tomivosertib and zotatifin into add...

                            Brand Name : eFT508

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 27, 2021

                            Lead Product(s) : Tomivosertib,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Locust Walk

                            Deal Size : $235.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Effector Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tomivosertib,Anti PD1/PD-L1 therapy

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            eFFECTOR’s Tomivosertib Shows Positive Phase 2 Results in Non-Small Cell Lung Cancer in Combination with Che...

                            Details : In a Phase 2 study, open-label study, tomivosertib demonstrated antitumor activity in combination with checkpoint inhibitors (CPI) in patients with solid tumors who progressed on CPI treatment.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 29, 2020

                            Lead Product(s) : Tomivosertib,Anti PD1/PD-L1 therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth